Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Outgoing Governor Eric J. Holcomb and Indiana Secretary of Commerce David Rosenberg recently highlighted the 2024 economic ...

Nearly 200 Eli Lilly and Co. employees from the Lebanon site under construction volunteered to distribute 75,000 diapers to ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...